IPHA vs MSFT: Which Stock is Better?
Side-by-side comparison of Innate Pharma Sa and Microsoft Corp in 2026
IPHA
Innate Pharma Sa
$1.69
MSFT
Microsoft Corp
$415.05
Key Metrics Comparison
| Metric | IPHA | MSFT | Winner |
|---|---|---|---|
| Market Cap | $152.94M | N/A | IPHA |
| P/E Ratio | N/A | 24.57 | MSFT |
| EPS (TTM) | $N/A | $16.00 | MSFT |
| Revenue Growth | -0.5% | 0.2% | MSFT |
| Gross Margin | -384.4% | 68.6% | MSFT |
Analyze IPHA
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is IPHA or MSFT a better investment?
Comparing IPHA and MSFT: Innate Pharma Sa has a market cap of $152.94M while Microsoft Corp has N/A. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between IPHA and MSFT?
IPHA (Innate Pharma Sa) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: IPHA or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: IPHA or MSFT?
MSFT has higher revenue growth at 0.2% vs -0.5% for IPHA.
Which company is more profitable: IPHA or MSFT?
Microsoft Corp (MSFT) has higher gross margins at 68.6% compared to -384.4% for IPHA.
Which is the larger company: IPHA or MSFT?
Innate Pharma Sa (IPHA) is larger with a market cap of $152.94M compared to N/A for MSFT.
Should I buy IPHA or MSFT in 2026?
Both IPHA and MSFT have investment merit. IPHA trades at $1.69 while MSFT trades at $415.05. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between IPHA and MSFT stock?
Key differences: Market Cap ($152.94M vs N/A), P/E Ratio (N/A vs 24.6x), Revenue Growth (-0.5% vs 0.2%), Gross Margin (-384.4% vs 68.6%).